Medtronic’s (MDT) Cardiac and Vascular Group (or CVG) is its largest segment. In fiscal 2016, the segment registered revenues at the high end of its targeted mid-single-digit growth range. Johnson & Johnson (JNJ), Edwards Lifesciences (EW), and Abbott (ABT) are Medtronic’s key competitors in this market segment.
Sustainable therapy innovation
Medtronic is a leading player in the cardiac and vascular market. The diagram above shows the CVG segment’s structure and recent performance. Investors can gain exposure to Medtronic’s growth potential by investing in the iShares S&P 500 Growth ETF (IVW). IVW has a ~0.76% exposure to MDT.
The diagram above shows how Medtronic’s innovative product portfolio has been a strong growth driver. Therapy innovation has consistently contributed approximately 250–350 basis points towards CVG revenues. CVG pipeline productivity has increased over the years, mainly due to the focus on and accountability for therapy innovation at the general manager level. The company focused on creating accountability, which thereby generated growth through transformative innovation, meaningful iterations, and scalable platform development. The company has also expanded its services and solutions business and evolved its business model in view of the changing industry landscape.